Literature DB >> 3018647

Treatment of AIDS-related Kaposi's sarcoma with recombinant gamma-interferon.

A Ganser, W Brücher, H R Brodt, W Busch, I Brandhorst, E B Helm, D Hoelzer.   

Abstract

Four patients with the acquired immunodeficiency syndrome and Kaposi's sarcoma were treated with subcutaneous human recombinant gamma-interferon at a dosage of 200 micrograms = 2 X 10(6) U twice daily for at least 28 days. While the dosage of interferon was well tolerated, progressive disease was observed in all four patients studied. These results might be due to the selection of the patients presenting advanced stages (3 out of 4) with recurrent disease after previous chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3018647     DOI： 10.1159/000215998

Source DB:  PubMed          Journal:  Onkologie        ISSN： 0378-584X


  10 in total

1.  Recombinant human gamma interferon enhances in vitro activation of lymphocytes isolated from patients with acquired immunodeficiency syndrome.

Authors:  W Heagy; T B Strom; V E Kelley; J Collela; C Crumpacker; J M Williams; H M Shapiro; L Laubenstein; R Finberg
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

2.  Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells.

Authors:  M Mercader; B Taddeo; J R Panella; B Chandran; B J Nickoloff; K E Foreman
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

Review 3.  Molecular genetics of Kaposi's sarcoma-associated herpesvirus (human herpesvirus-8) epidemiology and pathogenesis.

Authors:  Lyubomir A Dourmishev; Assen L Dourmishev; Diana Palmeri; Robert A Schwartz; David M Lukac
Journal:  Microbiol Mol Biol Rev       Date:  2003-06       Impact factor: 11.056

4.  A phase I trial of recombinant human interferon-gamma in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS).

Authors:  H C Lane; R T Davey; S A Sherwin; H Masur; A H Rook; J F Manischewitz; G V Quinnan; P D Smith; M E Easter; A S Fauci
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

5.  Treatment of atypical leishmaniasis with interferon gamma resulting in progression of Kaposi's sarcoma in an AIDS patient.

Authors:  H Albrecht; H J Stellbrink; G Gross; B Berg; U Helmchen; H Mensing
Journal:  Clin Investig       Date:  1994-12

6.  Risk of Classic Kaposi Sarcoma With Combinations of Killer Immunoglobulin-Like Receptor and Human Leukocyte Antigen Loci: A Population-Based Case-control Study.

Authors:  James J Goedert; Maureen P Martin; Francesco Vitale; Carmela Lauria; Denise Whitby; Ying Qi; Xiaojiang Gao; Mary Carrington
Journal:  J Infect Dis       Date:  2015-08-12       Impact factor: 5.226

7.  Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.

Authors:  B L Haagmans; P H van der Meide; F S Stals; A J van den Eertwegh; E Claassen; C A Bruggeman; M C Horzinek; V E Schijns
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

8.  Cell Type-Specific Interferon-γ-mediated Antagonism of KSHV Lytic Replication.

Authors:  Mi-Kyung Park; Hyejeong Cho; Seong Woon Roh; Seong-Jun Kim; Jinjong Myoung
Journal:  Sci Rep       Date:  2019-02-20       Impact factor: 4.379

9.  Interferon gamma induces the expression of human immunodeficiency virus in persistently infected promonocytic cells (U1) and redirects the production of virions to intracytoplasmic vacuoles in phorbol myristate acetate-differentiated U1 cells.

Authors:  P Biswas; G Poli; A L Kinter; J S Justement; S K Stanley; W J Maury; P Bressler; J M Orenstein; A S Fauci
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

Review 10.  Cytokine-Targeted Therapeutics for KSHV-Associated Disease.

Authors:  Nedaa Alomari; Jennifer Totonchy
Journal:  Viruses       Date:  2020-09-28       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.